First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot study
Introduction
Chronic heart failure affects around 100 million people worldwide imposing a significant burden on health care systems throughout the world. Even though symptoms are improved by heart failure therapy, they remain significantly disabling for many patients. Chronic over-activation of the sympathetic nervous system, is a major component of heart failure [1], [2], [3] and involves efferent and afferent pathways between brain and many organs [4].
A new therapy directly targeting nerve traffic—renal artery denervation—has been shown to be effective in drug-resistant hypertension, with an average drop in blood pressure of 33/12 mm Hg [5], [6]. Although in principle this intervention could be beneficial for improving the neurohormonal dysregulation of chronic heart failure [7], [8], there are concerns in practice because heart failure patients typically have normal or low blood pressure, and might therefore become symptomatically worse following renal denervation should blood pressure be lowered further.
We have therefore conducted a first-in-man study of 7 patients with chronic systolic heart failure, undergoing bilateral renal denervation, with an intensive protocol of observation and assessment comprising a 5-day hospital stay post procedure and 6 months of regular outpatient follow up.
Section snippets
Recruitment
In this first-in-man exploration, we sought to address a stable population of chronic systolic heart failure patients taking full prognostic therapy who would be willing to undergo prolonged inpatient assessment and intensive serial outpatient evaluation.
7 patients were recruited from the heart failure clinics of the campuses of Imperial College Academic Health Science Centre. Patients were required to have chronic symptomatic systolic heart failure (NYHA class III or IV) on maximal tolerated
Results
Bilateral denervation was successfully performed in all 7 patients. A minimum of 4 denervation therapies were delivered to each artery. There were no access site or other arterial complications associated with the procedure.
Discussion
In this first-in-man study of bilateral renal denervation in chronic systolic heart failure, there were no procedural complications or symptomatic adverse effects. The 5-day inpatient monitoring revealed no acute deleterious haemodynamic disturbances. In the longer term there was a trend towards blood pressure reduction over the 6 month follow up period which was small and did not achieve statistical significance. In all subjects markers of renal function remained stable with no clinical or
Conclusions
Bilateral renal denervation can be conducted safely in patients with chronic systolic heart failure. It appears well tolerated, with no haemodynamic disturbance during the immediate 5 days following the procedure nor any marked worsening in symptoms or renal function over a 6-month follow up period. A randomised, placebo-controlled blinded trial is required to evaluate whether renal artery denervation can achieve symptomatic improvements and increase objective functional measures such as walking
Conflict of interest
J.E. Davies and D.P. Francis are consultants for Medtronic Corp. and P. Sobotka receives royalties as a developer of the Ardian catheter system. No other author has a conflict of interest to declare.
Acknowledgements
R. Petraco (FS/11/46/28861), J.E. Davies (FS/05/006), and D.P. Francis (FS/10/038) are supported by the British Heart Foundation. The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology.
References (11)
- et al.
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
Lancet
(2009) - et al.
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Lancet
(2003) - et al.
Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure
Eur Heart J
(2005) - et al.
Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity
Circulation
(1986) - et al.
Arterial chemoreceptors and sympathetic nerve activity
Hypertension
(2007)
Cited by (246)
The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directives
2024, Current Problems in CardiologyNeuromodulation Therapies in Heart Failure: A State-of-the-Art Review
2023, Journal of the Society for Cardiovascular Angiography and InterventionsNeuromodulation interventions in the management of heart failure
2024, European Journal of Heart Failure